Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
PRICE
Prev Close
260.21
Open
257.96
Day Range255.61 – 258.91
255.61
258.91
52W Range190.75 – 267.47
190.75
267.47
85% of range
50-Day MA
254.35(+0.8%)
200-Day MA
228.31(+12.3%)
VOLUME & SIZE
Avg Volume
6.4M
FUNDAMENTALS
P/E (TTM)
25.2x
EPS (TTM)
—
Div Yield (TTM)
3.77%
High yield
Beta
0.36
Low vol
TECHNICAL
RSI (14)
56
Bullish momentum
ABBV News
About
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
